BioSpace News Archive

Jubilant Radiopharma’s Radiopharmacies division is excited to announce an investment of $50 million (USD) to expand its PET radiopharmaceutical manufacturing facilities by adding six (6) sites in strategic locations throughout the United States.

Researchers with City of Hope®, one of the largest cancer research and treatment organizations in the United States and a leading research center for diabetes and other life-threatening illnesses, presented novel study results at the 84th Scientific Sessions of ADA held June 21 to 24 in Orlando, Florida.

Precedence Research, the global over the counter (OTC) drugs market was evaluated at US$ 125.28 billion in 2023 and is expected to attain around US$ 229.01 billion by 2033, growing at a CAGR of 6.51% from 2024 to 2033.

Findings from the CATALYST study reveal that hypercortisolism may be a significant factor for why type 2 diabetes remains difficult to control for many patients.

Findings from the ATTEMPT study, showed that a low-dose of SGLT2 inhibitor could safely be given to youth and adolescents with type 1 diabetes to improve kidney function and glycemic management.

vTv Therapeutics Inc. (Nasdaq: VTVT), a late stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today announced that the first patient has been screened in the Company’s CATT1 pivotal trial evaluating cadisegliatin as an adjunct treatment of type 1 diabetes (T1D).

Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced that Paul Varki has joined the Company as its Chief Legal Officer.

Illumina, Inc. announced the successful completion of the spin-off of GRAIL. This milestone follows the company’s previously announced plans to divest GRAIL, and GRAIL is now a public and independent company.

Contineum Therapeutics, Inc. (Nasdaq: CTNM) today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (Nasdaq: RNA), as an independent member of its Board of Directors.